Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD | Market Cap | 39.04M -43.1% |
| Revenue (ttm) | 13.50M +7.9% |
| Net Income | -55.15M |
| EPS | -0.02 |
| Shares Out | 4.34B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 800,000 |
| Open | 0.0090 |
| Previous Close | 0.0090 |
| Day's Range | 0.0090 - 0.0090 |
| 52-Week Range | 0.0090 - 0.0400 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2026 |
About Radiopharm Theranostics
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung the... [Read more]
Financial Performance
In fiscal year 2026, Radiopharm Theranostics's revenue was 13.50 million, an increase of 7.91% compared to the previous year's 12.51 million. Losses were -55.15 million, 43.8% more than in 2025.
Financial StatementsNews
Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer
(RTTNews) - Radiopharm Theranostics (RADX), a clinical-stage biopharmaceutical company developing oncology radiopharmaceuticals, announced encouraging results from its Phase 1 imaging trial of RAD301 ...
Radiopharm announces data from imaging trial of RAD 301
Radiopharm (RADX) announced data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in healthy volunteers and subjects with Pancreatic Ductal Aden...
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting pote...
Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial
(RTTNews) - Radiopharm Theranostics (RADX), a clinical-stage biopharmaceutical company, on Tuesday announced that it has dosed the first patient in the second cohort of its First-In-Human Phase 1/2a c...
Radiopharm doses first patient in second cohort of RV-01 trial
Radiopharm (RADX) announced that it has dosed the first patient in the second cohort of its first-in-human Phase 1/2a clinical trial of RV-01 in patients with B7-H3 expressing tumors. This…
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, ...
Radiopharm Advances RAD202 Phase 1 Trial To Higher 180mCi Dose Level
(RTTNews) - Radiopharm Theranostics (RADX), a clinical-stage radiopharmaceutical company, announced that its Data Safety and Monitoring Committee (DSMC) recommended advancing 177Lu-RAD202 to Cohort 4 ...
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated cl...
Radiopharm Theranostics To Meet FDA On Phase 3 Design For RAD101; Phase 2b Shows 93% MRI Concordance
(RTTNews) - Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced that it has scheduled an End-of-Phase 2 meeting with...
Radiopharm schedules End-of-Phase 2 meeting with FDA for RAD101
Radiopharm (RADX) announced that it has scheduled an End-of-Phase 2 meeting with the FDA for October 1, to align on the design of a pivotal Phase 3 trial to evaluate…
Radiopharm announces $4.1M registered direct offering
Radiopharm (RADX) announced that it has entered into a securities purchase agreement, or SPA, with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1.282M Ame...
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on de...
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminar...
Radiopharm Theranostics trading halted, news pending
19:56 EDT Radiopharm (RADX) Theranostics trading halted, news pending
Radiopharm initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Radiopharm (RADX) with a Buy rating and $6 price target The company seeks to expand the cancer patient populations that may benefit from targeted radiotherapy,…
Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference
A differentiated radiopharmaceutical pipeline is advancing four clinical programs in parallel, with near-term catalysts expected from ongoing phase I and II trials. Imaging agent RAD 101 is nearing phase III and potential commercialization, while operational efficiency and strategic partnerships support growth.
Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference
Radiopharm Theranostics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (t...
Radiopharm Theranostics Earnings release: Q3 2026
Radiopharm Theranostics released its Q3 2026 earnings on April 22, 2026, summarizing the period's financial results.
Radiopharm announces new data from Phase 0/1 HEAT trial
Radiopharm (RADX) Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as ...
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
Radiopharm (RADX) announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the nex...
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Radiopharm Theranostics (RADX), 2566.66% surge in interes...
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinica...